|
|
|
|
Treximet is the first truly differentiated next-generation migraine product and it is being brought to market by the company that pioneered triptan therapy, gsk, and the scientific aspects of the product are being supported by more than 70 abstracts or full publications. Other agents on Fidelis Care's formulary that are available for this indication include generic alpha-1 antagonists e.g., doxazosin, terazosin ; , Flomax and Proscar. 3. Levaquin Moved to formulary status Tequin is moved to nonformulary status ; . Rationale: Levaquin is a fluoroquinolone which has a similar efficacy to Tequin and a more favorable cost profile. 4. Prevpac Moved to formulary status 7-day Aciphex-based regimen [Aciphex, Biaxin and Amoxicillin] moved to non-formulary status ; . Rationale: Prevpac is a combination treatment containing lansoprazole, clarithromycin and amoxicillin, and provides the convenience of one prescription for the treatment of H. pylori infection instead of three separate prescriptions ; , thus potentially improving adherence with therapy. 5. Synthroid Brand name formulations have been moved to formulary status. Rationale: In the context of the narrow therapeutic range associated with this agent, substitution with generic agents was deemed to have a potential to alter drug levels. Despite the availability of generic-rated equivalents, Fidelis will allow prescribing of brand name products without prior authorization. 6. Vytorin Added to the formulary without restrictions. Rationale: This is a combination of ezetimibe and simvastatin and is indicated for the management of hyperlipidemia. Prior Authorization Removed 1. Paxil, Paxil CR, Effexor and Effexor XR Prior authorization has been removed CHP formulary item ; . Rationale: Two advisory committees for the FDA the Psychopharmacologic Drugs Advisory Committee and Pediatric Drugs Advisory Committee ; have recently reviewed the data on the association between the use of 9 different antidepressants Prozac, Zoloft, Luvox, Serzone, Remeron, Paxil, Effexor, Wellbutrin, and Celexa ; and risk of suicidal ideation in pediatric patients.These committees did not recommend imposing a contraindication to the use of these agents in the pediatric population in the United States. Committee members did, however, recommend that a "black-box" warning regarding the increased risk of suicidal ideation in pediatric patients using antidepressants be included in the package inserts of all antidepressant agents.1 Step Therapy Criteria Added for Existing Formulary Agents or New Medications Added to Formulary with Step Therapy Requirement 1. Avandamet Added to the formulary with step therapy requirement. Rationale: This agent is a combination of rosiglitazone and metformin. The step therapy requirement allows providers to prescribe this combination treatment in patients with diabetes who are not adequately controlled on optimal doses of metformin alone. 2. Prevacidd Added to the formulary with step therapy requirement Protonix is moved to non-formulary status ; . Rationale: 0revacid is a proton pump inhibitor with similar efficacy to other proton pump inhibitors. This agent is FDA approved for multiple indications including reducing the risk of NSAID-induced gastric ulcers. Clarithromycin: Overdosage of clarithromycin can cause gastrointestinal symptoms such as abdominal pain, vomiting, nausea, and diarrhea. Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by hemodialysis or peritoneal dialysis. DOSAGE AND ADMINISTRATION H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence The recommended adult oral dose is 30 mg PREVACID, 1 g amoxicillin, and 500 mg clarithromycin administered together twice daily morning and evening ; for 10 or 14 days see INDICATIONS AND USAGE ; . PREVPAC is not recommended in patients with creatinine clearance less than 30 ml min. HOW SUPPLIED PREVPAC is supplied as an individual daily administration pack, each containing: PREVACID: Two opaque, hard gelatin, black and pink PREVACID 30-mg capsules, with the TAP logo and "PREVACID 30" imprinted on the capsules. Amoxicillin Capsules, USP: - Four yellow, opaque, hard gelatin amoxicillin 500-mg capsules, USP, imprinted AMOX 500 on one side and GG 849 on the other side. BIAXIN Filmtab: Two yellow oval film-coated clarithromycin 500-mg tablets, USP, debossed with the Abbott logo on one side and "KL" on the other side of the tablets. NDC 0300-3702-01 NDC 0300-3702-11 Daily administration pack Daily administration card. Side effects of PrevacidPrevacid side effectsRequest for Outpatient Retail Pharmacy Prior Authorization for Proton Pump Inhibitors Policy #030 ; Fax to: Clinical Pharmacy Program 800 ; 583-6289 or for Medicare HMO Blue and Medicare PPO Blue: 866 ; 463-7700 We plan to respond to your request within two business days of our receipt. To ensure that we can confirm your request required by NCQA ; , please be sure to include your fax number. We cannot process requests unless they contain all of the information requested below: Patient Information REQUIRED ; Name BCBSMA ID Number Is the patient a BCBSMA employee? If yes, please fax request to: 617 ; 246-4013 Date of Birth Patient's Diagnosis or ICD-9-CM code Physician Information REQUIRED ; Name Medical Specialty BCBSMA Provider number Telephone Number Fax Number Contact Name if different from physician ; Outpatient Retail Pharmacy Prior Authorization Request Step 1: Omeprazole 40mg Step 2: Protonix Step 3: Prevaciid Nexium Step 4: Aciphex overrides * Dose: Sig: Qty: * Please see lower box for QCD Yes No. The World Health Organisation WHO ; estimates that half of children worldwide live with at least one smoker. That has a profound effect on children's health from the direct health effects of inhaling second-hand smoke SHS ; , to the risks of house fires. Addiction to tobacco also perpetuates poverty, and leaves a lethal legacy to a new generation of smokers who have learned from their parents to use tobacco. In the United Kingdom UK ; , more than five million children under 16 are exposed to SHS in their homes. By July 2007, all enclosed public places in the UK will be smoke-free. As the ban on smoking in public places comes into law, we will see a reduction in the current level of tobacco related disease that still blights the UK and kills an estimated 109, 000 people each year. The evidence from other countries shows that smoke-free public places will protect workers from SHS, and will help smokers to quit. Furthermore, smoke-free places will reduce the numbers of our children who are exposed to SHS in their homes, and may prevent many from starting to smoke. There is no doubt that the smoke-free laws will benefit the UK's children, protecting their future health, and that of their families. The law, however, will not protect those children who remain exposed to tobacco smoke in utero, and to SHS in their own homes. The overwhelming majority of the world's children, however, live in countries where there is no legislative protection from SHS at all. This report describes the damage that adult smoking causes children. It explores effective ways of protecting some of the most vulnerable people in society from short and long-term harm, and recommends evidence-based policies that need to be adopted to break the cycle of children's exposure to tobacco smoke. As with other publications by the BMA Board of Science this report is aimed at a wide audience, including health professionals, policy makers and members of the public. The approach of the BMA's Board of Science is to provide a clear synthesis of the available research, and to develop evidence-based recommendations for policy and proventil. Prevacid pricesAt all times material hereto, tap and its management knewand understood that once a doctor prescribed prevacid to a patient in ahospital, prescription of prevacid to that patient would most likelycontinue upon the patient's discharge and prednisolone. It also reduces the potential for side effects occurring in other parts of the body, as the amount absorbed into the blood through the lungs is lower than if it is taken by mouth. Generic drugs are shown in lowercase italics e.g. digoxin ; Brand-name drugs are shown in capital letters e.g. PREVACID ; QL Drugs with Quantity Limits PA Drugs requiring Prior Authorization Please see page iv for a detailed description of this legend and prednisone. Signs of toxicity can occur with acute overdoses or long-term use. Signs include lack of appetite, vomiting, stumbling, nystagmus eyes move rapidly back and forth ; , knuckling over at the joints, disorientation, stiffness, rigidity, and seizures. Signs may not resolve until the pet is off of the medication for several days. P revacid lansoprazole ; generic name: lansoprazole side effects as reported by the pdr family guide to prescription drugs why is this drug prescribed: prevacid blocks the production of stomach acid and ventolin. Defendants, including Merck for its drug Pepcid and TAP for its drug Prevacid to select just two examples ; , make unlawful use of the so-called "nominal price" exception by omitting certain deeply discounted commercial sales and other sales from their Best Price calculation. V. 133. DEFENDANTS CONCEAL THEIR TRUE PRICES Defendants have been able to succeed in their drug pricing scheme for. 4.6.3 AstraZeneca Facing EU Patent Abuse Charges Concerning Losec 4.7 Protonix is another Leading PPI Facing Patent Expiry later this Decade 4.7.1 Protonix is a Strong Performer with Increasing Revenues from 2002-2005 4.7.2 Protonix Benefited from Early FDA Approval for Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome 4.8 Pantozol will Experience Patent Expiry, Leading to a Sharp Decline in Revenue 4.8.1 Wyeth Acts as a Partner for Sales of Pantoprazole in the US 4.8.2 Patent Protection for Pantoprazole Extended to 2010 in the US; Similar Protection in Europe - Altana Optimistic Over Continuing Revenue Growth 4.8.3 Pantozol Continues to Perform Well in 2005 4.8.4 Sales in Germany Declined Slightly Due to Mandatory Discount - Altana Challenges State's Decision 4.9 Takepron will Supplant Nexium to Become the Leading PPI 4.9.1 Takeda Developed Lansoprazole 4.9.2 Revenues for Takepron During Part of 2005 Revealed Disappointing Growth Rate 4.10 Aciphex Pariet will Continue to Grow Moderately in Revenue 4.10.1 Eisai's Long-Running Commercial Arrangement with Johnson & Johnson for Aciphex Pariet 4.10.2 Eisai Commences US Legal Actions Over ANDA Filings for Generic Versions of Aciphex Pariet 4.10.3 Eisai Receives European Marketing Authorization for PARIET for ZollingerEllison Syndrome 4.10.4 Eisai Applies For A New Indication for Pariet in Japan for Eradicating H. Pylori 4.10.5 New Production Facilities for Aciphex Pariet Incorporate Latest Technology to Achieve Cost Savings 4.11 Zoton's Loss of Patent Protection will Cause this Product Difficulties in the Market 4.11.1 Zoton Displayed Increasing Revenues Until 2004 but Faced a Downturn in 2005 4.11.2 Zoton Released in OTC Form - How well will it Compete with Prilosec OTC and Other Preparations? 4.12 Prevacid Ogastro and flonase. All that water is flushing everything out. Cell, 83: 993-1000, 199 stott fj, bates s, james mc, et al the alternative product from the human cdkn2a locus, p14 arf ; , participates in a regulatory feedback loop with p53 and mdm embo j, 17: 5001-14, 199 bates s, phillips ac, clark pa, et al p14arf links the tumour suppressors rb and p5 nature, 395: 124-5, 199 de stanchina e, mccurrach me, zindy f, et al e1a signaling to p53 involves the p19 arf ; tumor suppressor and decadron. Distinguish the HHRH from the other causes of hypophosphatemic rickets. The most recent evidences show that HHRH is associated to mutations that affect the two alleles of gene SLC34A3, responsible for NaPiT-II co-transporter activity, rendering the cotransporter inactive 19 ; . The heterozygotes for mutation in SCL34A3 gene present hypercalciuria with mild or absent hypophosphatemia 19 ; . Studies of the 3 main types of hypophosphatemic rickets XHR, ADHR and TIO ; suggest a common pathophysiologic underlying mechanism: hyperphosphaturia secondary to reduction of tubular phosphate reabsorption. Researches on these diseases indicate the existence of a metabolic bone-renal axis capable to regulate the phosphorus homeostasis and the bone mineralization. FGF-23 seems to have a central role on this axis 2, 3, 34 ; through its phosphaturic action and its autocrine action on osteoblasts, modulating, thus, bone mineralization. Alterations in FGF23 metabolism, due to inhibition of its proteolytic cleavage or to its increased resistance to proteolysis, trigger disturbances in phosphorus homeostasis and in bone-mineral metabolism. Some authors suggest that the osteoblasts are the candidate cells to assume the metabolic coordination of this bone-renal axis, once they synthesize proteins that have important role in phosphorus homeostasis and in osteoid mineralization, including FGF23, Phex, MEPE, and express elements that regulate bone mineralization, bone mass and renal phosphate conservation 3. Dr. Alzohali, Takeda, Actos L. Goetz, PharmD, P&G, Actonel, Prilosec OTC R. Pannone, PharmD, Amgen, Enbrel G. Katz, MD, Alcon, Vigamox, Travatan, Patanol J. Baker, PharmD, Astellas, Vesicare, Protopic B. Facca, PharmD, GSK, Migraine products and Treximet D. Smith, MD, M. Bodenschatz, Eli Lilly, insulin products G. Anderson, PhD, AstraZeneca, Nexium M. Stevens, PharmD, TAP, Prevacid and PPI Class S. Scarbrough, Biogen Idec, Avonex S. Robinson, RPh, Amylin, Byetta S. Chase, PharmD, Forest, Bystolic P. Sardo, PharmD, Abbott, Simcor, Humira Dr. Lavery, Dr. Rosenberg, Allergan, Combigan, Sanctura G. Engelmann, PhD, Alpharma, Flector D. Iacobellis, PharmD, Pfizer, Detrol LA D. Vinson, MD, Shire, Lialda S. Servera, MD, Novo Nordisk, analog insulins and FlexPen and rhinocort. MUNICIPAL CORPORATION OF THE CITY OF THANE LIST OF PROPERTIES HAVING OUTSTANDING AS ON 31 2006 WARD OFFICE : RAILADEVI BLOCKNO : 56 Page No : 59 PROP.NO. H.NO. NAME OF OWNER HOLDER OUTSTANDING AMT 8032312 SHRI. RAMAKANT VITTHAL BHABAD 1269.00 80 OPP PATHAN ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030412 STRU.M. SHR. JAGNATH H. BANSODE 103.00 80 BEHIND KAMBALE MASALE SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030370 STRU.M. SHR. PRABHU CHOWAN 546.00 81 NEAR ASHOK PATANE'S HOUSE ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030488 STRU.M. SHR. MATHADIST TAMIL CHIRCH 183.00 81 BEHIND MADINA MATAN SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030200 STRU.M. SHR. KISAN DYNU MORE 183.00 83 NEAR MADINA MATAN SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030405 MRS. PRABHAVATI NIVRUTI KAKAD 255.00 84 NEAR CHANDANI CHOUK, NEAR FLOUR MILL ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030390 STRU.M. SHR. CHANDARKANT NAMDEV CHOWAN 681.00 84 NEAR FLOUR MILL ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030387 STRU.M. SHR. RIYAJ HUSEN PADEKAR 229.00 84 NEAR FLOUR MILL ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030386 STRU.M. SHR. NARAYAN LAXMAN COTAKAR 426.00 84 NEAR FLOUR MILL ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030396 STRU.M. SMT. SANGEETA SAJJAN GORDE 284.00 85 BEHIND KAMBALE MASALE SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030403 STRU.M. SHR. DATTARAM SAKHARAM GHAG 176.00 85 NEAR CHANDANI CHOUK, NEAR WELL ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030451 SHRI. KRUSHNA NARAYAN NIVATE 167.00 85 BEHIND KAMBALE MASALE SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030457 STRU.M. SHR. CHANDARKANT DAJI MAHATRE 409.00 85 IN FRONT OF KAMBALE MASALE SHOP ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE 8030493 STRU.M. SMT. JAGANADEVI KANTAPRASAD 176.00 86 JAISWAL IN FRONT OF SHIVSENA SHAKHA ROAD NO.28 KAILAS NAGAR WAGLE ESTATE THANE. Bussau et al., 2006 ; . However, the impact of prolonged intermittent high intensity exercise patterns on the postexercise glucose responses of T1DM patients is unclear. The aim of this study was to compare the metabolic responses of T1DM patients following intermittent and continuous exercise. With local ethics committee approval and informed consent 9 non-diabetic ND ; and 9 T1DM patients participated in this study. Physical and physiological characteristics of ND and T1DM respectively were meanSD age: 277, 3512 years; body mass: 796, 8412 kg; HbA1c: 5.30.3, 8.10.6 %; VO2max: 48.38.8, 41.84.9 ml kg min-1. After two preliminary visits participants completed two main 45 min exercise trials in a randomised order, an intermittent running protocol designed to simulate intermittent games play INT, Nicholls et al., 2000 ; and a continuous treadmill run CON ; that matched the mean rate of oxygen consumption of INT. Venous blood samples 10 ml ; were taken at rest and for 3 h post-exercise to determine blood glucose and lactate concentrations. A continuous glucose monitor measured interstitial glucose concentrations for 24 h post-exercise. Data were analysed using a two-way ANOVA with post-hoc testing where appropriate and significance was established at P 0.05. The rate of oxygen consumption expressed as a percentage of VO2max ; was similar between conditions ND: CON 725, INT 735; T1DM: CON 778, INT 775 %, NS ; . Peak blood lactate concentrations were greater in INT compared with CON INT: ND 6.83.0, T1DM 9.52.8 mM vs. CON: ND 1.90.8, T1DM 3.72.1 mM, P 0.05 ; . Blood glucose concentration decreased significantly in T1DM compared to ND immediately after CON ND 0.61.0 vs. T1DM -4.12.9 mM, P 0.05 ; and INT CON 1.71.1 vs. T1DM -1.54.3 mM, P 0.05 ; and remained lower for 3 h post-exercise P 0.05 ; . Interstitial 24 h AUC glucose profiles were greater in T1DM compared to ND T1DM: CON 2432922, INT 2542547 mM.24 h-1 vs. ND: CON 1540262, INT 159869 mM.24 h-1, P 0.05 ; but there was no significant difference between INT or CON conditions within each group. The results demonstrate a significant reduction in blood and interstitial glucose concentrations of T1DM patients following both INT and CON exercise. However, there were no significant differences in glucose concentrations between the exercise types when performed at the same physiological intensity, despite a different anaerobic contribution. These data suggest the pattern of exercise does not influence the degree of postexercise hypoglycaemia when the oxygen demand of exercise is similar and serevent and Order prevacid. Jacqueline marcell: it is called the more-so theory of aging. CRAFTSMAN" Creeper Seat - .00 O.B Prescription Eyeglasses Custom made to your prescription, stylish plastic or metal frame, Highindex, UV protection, antiscratch lens, case, lenscloth for only . Also available: Rimless, Titanium, Children's, Bifocals, Progressives, Suntints, ARcoating, etc. : ZENNIOPTICAL AAN CAN ; Books for Sale , Menlo Park - .69 Books of-all-kinds For Sale - .69 Construction: Trench Plates - $varies Deluxe `07 Hot tub w warranty. Many jets. Therapy seats. Worth over 00. Sell 50. Can deliver. 408 732-1062 DIRECTV Satellite Television, FREE Equipment, FREE 4 Room Installation, FREE HD or DVR Receiver Upgrade w rebate. Packages from .99 mo. Call 800380-8939. AAN CAN ; ExecMgmt Consultant - 0 grave plot Double decker grave plot in section A Holy Cross Cemetary, Menlo Park. 408-732-7341 Power Wheelchairs and Scooters at little or no cost to seniors disabled with Medicare, MediCal or Insurance. Free Delivery, Training and Warranty. ProHealth Mobility. 1-877-740-4900. ProHealthMobility Cal-SCAN ; Table Saw - 0.00 teacup yorkie - ##TEXT##0 and astelin. Re: Children's Hospital of Buffalo Neglects and Endangers Children! What's even crazier was the fact that the nurses couldn't properly convert the kilograms to pounds and ounces! One conversion showed Cody at 7lbs 4ozs when in fact he was 7lbs 14ozs - but wait -- that was the weight done with the blanket -- so again, IT DIDN'T COUNT! If only this were the only problem!!! 2. Saturday, Cody was to have a sonogram to check to see if he needed surgery - he didn't. They wouldn't let him eat in the emergency room and then they wouldn't let him eat before the sonogram - in case surgery was needed. Sounds reasonable until you find out that he couldn't have the sonogram until 3PM Saturday and withholding food was only necessary six hours before the surgery - if it had been needed which it wasn't. According to the attending doctor, the surgery wouldn't have been preformed until sometime the following day - if it had been needed -- which it wasn't - Cody would have gone 36 hours or more without food instead of the 24 hours he went without food! A infant, already losing weight and no one could get on the same page as to feeding him. The attending stated that the resident incorrectly thought that Cody would be rushed into surgery immediately and that's why he wasn't fed. The resident blamed the surgeons - in any case.THE INFANT WASN'T FED FOR NEARLY 24 HOURS! If only the problems ended here!!! 3. Cody was placed on Prevacid for reflux. He was to be given the first dose at 8pm on Saturday. The dose never came. Calls were made to the hospital pharmacy - but no one could give an answer until the following morning when everyone concluded that the pharmacy goes by STANDARD TIMES when dispensing medication. A once a day medication would be dispensed at 8AM unless the doctor insists. The resident planned on Cody being given the first dose right away and informed the parents of that fact - but the resident never insisted! So, Cody got the medication nearly 12 hours later than was intended and no one informed the parents who were in his room ; - they would have insisted on the earliest possible dose. Prevacid is a fairly new medication for reflux that takes 4 - 7 days to start working. Had the parents been told this fact - they would have immediately requested a different medication - Zantac! Instead, the attending doctor touted the drug as an improvement on Zantac. You may have heard of Prevacid in the news - several arrests were made due to the marketing practices of the drug company! The drug is not currently made in a generic form, so if it is prescribed - all profits currently go to the only source - the drug manufacturer. So, how do they get doctors to prescribe Prevacid? They lavish CASH & SKI TRIPS & GOLF VACATIONS on the Doctors who prescribe it! It is a shame that this is how things are done. So, once the Budnacks knew that the medication took so long to work - Children's Hospital of Buffalo Neglects and Endangers Children! 2. These adenomas in rats receiving doses of 15 to 150 mg kg day 4 to 40 times the recommended human dose based on BSA ; exceeded the low background incidence range 1.4 to 10% ; for this strain of rat. Testicular interstitial cell adenoma occurred in 1 of rats treated with 50 mg kg day 13 times the recommended human dose based on BSA ; in a 1-year toxicity study. In a 24-month carcinogenicity study, CD-1 mice were treated orally with doses of 15 to 600 mg kg day, 2 to 80 times the recommended human dose based on BSA. Lansoprazole produced a dose-related increased incidence of gastric ECL cell hyperplasia. It also produced an increased incidence of liver tumors hepatocellular adenoma plus carcinoma ; . The tumor incidences in male mice treated with 300 and 600 mg kg day 40 to 80 times the recommended human dose based on BSA ; and female mice treated with 150 to 600 mg kg day 20 to 80 times the recommended human dose based on BSA ; exceeded the ranges of background incidences in historical controls for this strain of mice. Lansoprazole treatment produced adenoma of rete testis in male mice receiving 75 to 600 mg kg day 10 to 80 times the recommended human dose based on BSA ; . Lansoprazole was not genotoxic in the Ames test, the ex vivo rat hepatocyte unscheduled DNA synthesis UDS ; test, the in vivo mouse micronucleus test or the rat bone marrow cell chromosomal aberration test. It was positive in in vitro human lymphocyte chromosomal aberration assays. Lansoprazole at intravenous doses of up to mg kg day approximately 8 times the recommended human dose based on BSA ; was found to have no effect on fertility and reproductive performance in male and female rats. Pregnancy: Teratogenic Effects Pregnancy Category B Teratology studies have been conducted in rats and rabbits using intravenous lansoprazole doses of up to mg kg day approximately 8 times in rats and 16 times in rabbits of the recommended human dose based on BSA ; . Treatment with lansoprazole did not result in any impairment of fertility or harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women using the intravenous route. Because animal reproduction studies are not always predicative of human response, PREVACID I.V. for Injection should be used during pregnancy only if clearly needed. Nursing Mothers Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue PREVACID I.V. for Injection, taking into account the importance of PREVACID I.V. for Injection to the mother. Pediatric Use The safety and effectiveness of PREVACID I.V. for Injection have not been established for pediatric patients. For further information, please see the PREVACID package insert for the oral formulations. Use in Women Among intravenous PREVACID treated subjects, similar percentages of adverse events were reported in males and females. Over 4, 000 women were treated with oral PREVACID. Ulcer healing rates in females were similar to those in males. The incidence rates of adverse events in females were also similar to those seen in males. Use in Geriatric Patients Data in elderly patients administered intravenous lansoprazole is limited; however, with oral lansoprazole, ulcer healing rates in elderly patients are similar to those in a younger age group. The incidence rates of PREVACID-associated adverse events and laboratory test abnormalities are similar to those seen in younger patients. For geriatric patients, dosage and administration of PREVACID need not be altered for a particular indication. ADVERSE REACTIONS Clinical Safety Experience with PREVACID I.V. for Injection More than 1, 000 patients and subjects have participated in domestic and foreign clinical trials. Treatment with PREVACID I.V. for Injection was well-tolerated. In four U.S. trials involving 161 subjects exposed to PREVACID I.V. for Injection, the following treatment-related adverse events were reported in 1% of subjects: headache 1.0% ; , injection site pain 1.0% ; , injection site reaction 1.0% ; and nausea 1.3% ; . Treatment-related adverse events occurring in less than 1% of subjects included abdominal pain, vasodilatation, diarrhea, dyspepsia, vomiting, dizziness, paresthesia, rash, and taste perversion. No additional adverse drug reactions were reported with the intravenous formulation that had not been reported previously with the oral formulations. Clinical Safety Experience with Oral Formulations of PREVACID Worldwide, over 10, 000 patients have been treated with oral PREVACID in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment. In general, PREVACID treatment has been well-tolerated in both short-term and long-term trials. The following adverse events were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of PREVACID-treated patients and occurred at a greater rate in PREVACID-treated patients than placebo-treated patients in Table 4. Table 4: Incidence of Possibly or Probably Treatment-Related Adverse Events in Short-Term, Placebo-Controlled PREVACID Studies PREVACID Oral N 2768 ; % 2.1 1.0 3.8 Placebo N 1023 ; % 1.2 0.4 2.3. Lifestyle modifications, approval for maintenance therapy may be given for an additional 12 weeks of treatment. Positive H. pylori If the patient has tested positive for H. pylori breath test, blood test or tissue biopsy if endoscopic exam done ; and met prior usage requirements, approval may be given for up to 2 weeks of combination therapy. Requests for Prevpac should meet Prevpac criteria, not PPI criteria. Gastric ulcer, duodenal ulcer, or esophagitis The patient must have an appropriate diagnosis confirmed by testing barium contrast or double contrast radiography, or endoscopy ; within the past 12 months and meet prior usage requirements. If these requirements are met, up to 8 weeks of acute therapy may be approved. If on completion of 8 weeks of acute treatment for esophagitis erosive or non-erosive ; symptoms persist, approval may be given for up to 6 months of maintenance treatment. After 12 months, approval will require documentation of persistent symptoms and the results of retesting. Hypersecretory Conditions If the patient is diagnosed with Barrett's Esophagitis, Zollinger-Ellison, or other hypersecretory disorders, which have been confirmed by testing barium contrast or double contrast radiography, or endoscopy ; , then approval of up to months of acute treatment may be issued, with continued maintenance therapy approved in 12 month increments. Renewal requests do not require retesting but do need documentation of persistence of symptoms. For Prevacid NapraPacTM the patient must have a diagnosis of gastric ulcer, diagnosed within the past 12 months, and require the use of an NSAID for treatment of the signs and symptoms of rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis. The patient must also have failed two 30 day treatment trials with at least two prescribed NSAIDs while on concomitant H2 or PPI therapy within the past 6 months, either generic, OTC or brand, or have a documented contraindication to all preferred agents in this class. For Prevpac the patient must have a diagnosis of duodenal ulcer, confirmed by testing within the past 12 months, and must also test positive for H pylori, confirmed by testing within the past 30 days. The patient must have failed two acute treatment trials of at least 14 days each with lack of healing on an acid suppressor and antibiotics, either generic, OTC or brand, within the past 6 months or have a documented contraindication to all preferred agents in these classes. If the drug requested is a Narcotic Analgesic, medical justification may be submitted in lieu of prior usage requirements and may consist of diagnosis and ICD-9 codes, documentation of therapeutic pain management failure with NSAIDs, APAP, or ASA and must consist of a complete pain evaluation in the medical record. Type of pain acute versus chronic ; and pain intensity mild, moderate or severe ; must be indicated in the Drug Clinical Information section, Medical Justification. Approval may be given for children age 18 years and under who have been stable on the requested medication for 60 consecutive days or greater. The original start date of the requested medication must be provided with an indication of why the specific brand requested is medically necessary. Prevacid medicinePrevzcid, prevac9d, orevacid, prevacjd, prsvacid, revacid, prevacie, prevaicd, ptevacid, prevaid, preacid, prrevacid, precacid, prevackd, prrvacid, prevacod, prevadid, pevacid, pr3vacid, rpevacid, prevcid, prdvacid, prevavid, prevacir, pregacid, preavcid, prebacid, prevacidd, prevcaid, prevaxid, prevwcid, pdevacid, prevac8d. | |
| © 2006-2007 Web-buy.fizwig.com -All Rights Reserved. |
